# **Quarterly Update/Target price/Rating change**

# Insecticides India

India | Agrochemicals



### Product launches to drive growth

### Declining raw materials price aiding margin expansion

Insecticides India (INST IN) reported a 10% decline in top line to INR 2.7bn. Gross margin expanded by 1,945bp to 31.9%, ahead of our estimates of 759bp increase, led by low cost raw materials purchases. Consequently, EBITDA came in at INR 89mn vs an EBITDA loss of INR 283mn in Q4FY23. Management's focus on growing a Maharatna range of molecules, up 27%, and new launches gained traction.

### Product launches and brand building on the rise

INST launched eight products in FY24, which generated INR 510mn in revenue this year. It plans to launch another 7-8 molecules in FY25. The upcoming launches would be more in the herbicides category for crops, such as sugarcane, paddy, maize and wheat. Brand-building activities and engagements with Indian actor Ajay Devgan resulted in higher demand for key products.

### Backward integration to bolster margin expansion

The company is expanding capacity of technical and active ingredients at Dahej in Gujarat and Sotanala in Rajasthan. The Dahej plant is complete and awaits few approvals from the State government. INST is doing phase-wise capacity expansion of technical and formulations at Sotanala. The first phase is likely to start by end-FY25 while the second phase will operationalize from FY26-end.

### Valuation: revise to Accumulate with a lower TP of INR 593

Management expects to achieve double-digit, topline growth in FY25, led by good demand for newly launched products. We expect healthy margin improvement, driven by better product mix and a decline in price of generic molecules, wherein price pass-through to end consumers has been lower. We trim our EBITDA estimates by 12% and PAT by 10% in FY25 and by 7% & 6% in FY26, respectively. We change to Accumulate from Buy with a lower TP of INR 593 from INR 629 based on 10x (unchanged) FY26E EPS of INR 59.3.

## Rating: Accumulate

**Target Price: INR 593** 

Upside: 12%


CMP: INR 531 (as on 30 May 2024)

Key data	
Bloomberg / Reuters Code	INST IN/INST.BO
Current /Dil Shares O/S (mn)	30/30
Mkt Cap (INR bn/USD mn)	16/190
Daily Volume (3M NSE Avg)	43,593
Face Value (INR)	10

#### 1 USD = INR 83.3

Note: \*as on 30 May 2024; Source: Bloomberg

#### Price & Volume



Source: Bloomberg

Shareholding (%)	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Promoter	72.2	72.2	72.2	72.2
Institutional Investor	16.6	14.6	13.6	13.5
Other Investor	3.4	3.8	3.9	3.8
General Public	7.9	9.4	10.4	10.6

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	2.3	11.7	20.7
Insecticides India	(1.2)	(19.6)	14.1
Rallis India	3.2	9.9	34.0
UPL	7.7	(11.3)	(26.6)
PI Industries	(3.1)	(5.7)	2.5
Carriago Dia anakana			

Source: Bloomberg

Consolidated financials (INR Mn)	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)	FY24	FY23	YoY (%)
Cons Net Sales	2,725	3,019	(9.7)	3,579	(23.9)	19,664	18,013	9.2
Raw Materials	1,857	2,644	(29.8)	2,500	(25.7)	14,650	13,856	5.7
% of Net Sales	68.1	87.6	(1,945)bp	69.8	(171)bp	74.5	76.9	(242)bp
Employee Cost	258	217	19.1	278	(7.0)	1,173	984	19.3
Other Expenses	521	441	18.1	542	(3.8)	2,212	1,954	13.2
Total Expenditure	2,636	3,302	(20.2)	3,319	(20.6)	18,035	16,794	7.4
EBITDA	89	(283)	(131.5)	260	(65.7)	1,629	1,219	33.6
Margin (%)	3.3	(9.4)	1,265bp	7.3	(399)bp	8.3	6.8	151bp
Depreciation	76	66	14.3	74	2.5	293	261	12.1
EBIT	13	(350)	(103.8)	186	(92.9)	1,336	958	39.5
Interest	21	45	(53.6)	28	(25.6)	109	135	(19.1)
Other Income	45	4	1,000.7	12	267.2	95	13	655.0
PBT	38	(390)	(109.7)	170	(77.8)	1,322	836	58.1
Tax	(40)	(100)	(60.1)	48	(183.8)	299	206	45.0
Tax Rate (%)	(105.9)	25.7	(13,156)bp	28.0	(13,387)bp	22.6	24.7	(205)bp
RPAT	78	(290)	(126.8)	123	(36.7)	1,023	630	62.4
APAT	78	(290)	(126.8)	123	(36.7)	1,023	630	62.4
Adj EPS (INR)	3.9	(14.7)	(126.8)	6.2	(36.7)	51.9	31.9	62.4

YE	Revenue	YoY	EBITDA	EBITDA	Adj PAT	YoY	Fully DEPS	RoE	RoCE	P/E	EV/EBITDA
March	(INR mn)	(%)	(INR mn)	margin (%)	(INR mn)	(%)	(INR)	(%)	(%)	(x)	(x)
FY23	18,013	19.8	1,219	6.8	630	(41.2)	21.3	6.9	8.9	25.0	14.0
FY24E	19,664	9.2	1,626	8.3	1,021	61.9	34.5	10.1	12.2	15.4	9.8
FY25E	22,613	15.0	2,205	9.8	1,442	40.9	48.7	12.2	15.2	10.9	7.0
FY26E	25,327	12.0	2,634	10.4	1,747	21.1	59.0	12.9	16.3	9.0	5.6




### **Consolidated Financials (YE March)**

Consolidated Financ	.iais (1	re iviai	CH	
Income Statement (INR mn)	FY23	FY24	FY25E	FY26E
Net Revenues	18,013	19,664	22,613	25,327
EBITDA	1,219	1,626	2,205	2,634
Less: - Depreciation & Amortization	261	293	340	412
EBIT	958	1,333	1,865	2,222
Less:- Interest Expenses	135	109	57	22
Add:- Non operating Income	13	95	102	110
PBT	836	1,319	1,911	2,311
Less :- Taxes	206	298	459	555
Adjusted PAT	630	1,021	1,452	1,757
Reported PAT	630		1,452	1,757
		1,021		
Balance Sheet (INR mn)	FY23	FY24	FY25E	FY26E
Share Capital	296	296	296	296
Reserves	8,861	9,839	11,536	13,290
Borrowings	1,591	832	431	50
Deferred Tax (Net)	127	100	100	100
Trade Payable	4,483	4,190	5,266	5,898
Other Liabilities	1,580	1,877	2,008	2,241
Total Liabilities	16,937	17,135	19,637	21,876
Gross Block	3,762	4,126	5,580	6,180
Less:- Accumulated Depreciation	1,394	1,687	2,026	2,438
Net Block	2,368	2,439	3,554	3,742
CWIP	1,175	1,354	500	500
Other Non-Current Assets	1,075	860	1,120	1,177
Cash & bank balances	194	614	762	1,111
Inventory	8,617	8,069	9,293	10,408
Trade Receivable	2,962	2,967	3,593	4,025
Other Net Assets	545	832	815	913
Total Assets	16,937	17,135	19,637	21,876
	FY23	FY24	FY25E	FY26E
Cash Flow Statement (INR mn)				
Cash profit adjusted for non-cash items	1,213	1,712	2,205	2,634
Add/Less: Working Capital Changes	(1,013)	260	(591)	(779)
Taxes Paid	(306)	(135)	(436)	(527)
Operating Cash Flow	(106)	1,837	1,178	1,328
Less:- Capex	(859)	(436)	(600)	(600)
Free Cash Flow	(965)	1,401	578	728
Financing Cash Flow	797	(981)	(530)	(490)
Investing Cash Flow	(867)	(430)	(498)	(490)
Net change in Cash	(176)	427	150	349
Ratio Analysis	FY23	FY24	FY25E	FY26E
Income Statement Ratios(%)				
Revenue Growth	19.8	9.2	15.0	12.0
EBITDA Growth	(28.2)	33.4	35.6	19.5
PAT Growth	(41.2)	61.9	40.9	40.9
EBITDA Margin	6.8	8.3	9.8	10.4
Net Margin	3.5	5.2	6.4	6.9
Return & Liquidity Ratios (%)	3.3	3.2	0	0.7
Net Debt/Equity (x)	0.2	0.0	(0.0)	(0.1)
ROE (%)	6.9	10.1	12.2	12.9
ROCE (%)	8.9	12.2	15.2	16.3
Per Share data & Valuation Ratios	0.7	12.2	13.2	10.5
	21.2	24.5	40.1	FO 3
Diluted EPS (INR)	21.3	34.5	49.1	59.3
EPS Growth (%)	(60.8)	62.0	42.3	21.0
DPS (INR)	3.0	1.7	2.4	3.0
P/E (x)	25.0	15.4	9.8	-
EV/EBITDA (x)	14.0	9.8	7.0	5.6
EV/Sales (x)	1.0	8.0	0.7	0.6
BVPS (INR)	309	342	400	459
Price/Book (x)	1.7	1.6	1.3	1.2
Dividend Yield (%)	0.6	0.3	0.5	0.6
	mpany Flar	2 Socurities E		


Note: Pricing as on 30 May 2024; Source: Company, Elara Securities Estimate

### Revenue growth & margin trend




Source: Company, Elara Securities Estimate

### Adjusted profit growth trend



Source: Company, Elara Securities Estimate

### **Return ratios**



Source: Company, Elara Securities Estimate



Exhibit 1: Change in estimates

(INR mn)	Old		Nev	/	Change	: (%)
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Net sales	23,305	25,635	22,613	25,327	(3.0)	(1.2)
EBITDA	2,494	2,846	2,205	2,634	(11.6)	(7.4)
EBITDA margin	10.7	11.1	9.8	10.4	(95)bp	(70)bp
Adjusted PAT	1,612	1,861	1,452	1,757	(9.9)	(5.6)
EPS (INR)	54.4	62.9	49.1	59.3	(9.8)	(5.7)
Target price (INR)		629		593		(5.7)
Rating		Buy		Accumulate		

Source: Elara Securities Estimate



# **Coverage History**



\*AC = Analyst Change

	Date	Rating	Target Price	Closing Price
22	11-Feb-2022	Accumulate	INR 792	INR 753
23	27-May-2022	Accumulate	INR 869	INR 770
24	17-Aug-2022	Reduce	INR 968	INR 1,008
	9/30/2022#	Reduce	INR 645	INR 718
25	7-Nov-2022	Sell	INR 678	INR 739
26	14-Feb-2023	Accumulate	INR 659	INR 583
27	31-May-2023	Accumulate	INR 469	INR 445
28	11-Aug-2023	Reduce	INR 469	INR 470
29	3-Nov-2023	Reduce	INR 502	INR 520
30	6-Feb-2024	Accumulate	INR 629	INR 593
31	6-Mar-2024	Buy	INR 629	INR 517
32	30-May-2024	Accumulate	INR 593	INR 531

#Bonus 1:2

## **Guide to Research Rating**

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%



### Elara Securities (India) Private Limited

#### Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information, Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

### Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

### Elara Securities (India) Private Limited



#### Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

#### Disclosures for U.S. Investors

The research analyst did not receive compensation from Insecticides India Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Insecticides India Limited.

Elara Capital Inc.'s affiliate did not receive compensation from Insecticides India Limited in the last 12 months.

Elara Capital Inc.'s affiliate does not expect to receive compensation from Insecticides India Limited in the next 3 months.

#### Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



## Elara Securities (India) Private Limited

Europe	USA	Asia / Pacific
Elara Capital Plc.	Elara Securities Inc.	Elara Capital (Asia) Pte.Ltd.
6th Floor, The Grove,	230 Park Avenue, Suite 2415, New	One Marina Boulevard,
248A Marylebone Road,	York, NY 10169, USA	Level 20,
London, NW1 6JZ, United Kingdom	Tel: +1 212 430 5870	Singapore 018989
Tel: +44 20 7486 9733	Fax: +1 212 208 2501	Tel: +65 6978 4047
	Elara Capital Plc. 6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom	Elara Capital Plc. 6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom Elara Securities Inc. 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870

Tel: +91 22 6164 8500		Tel : +44 20 7486 9733	Fax: +1 212 208 2501 Te	el : +65 6978 4047
Harendra Kumar	Managing Dire	ector	harendra.kumar@elaracapital.com	+91 22 6164 8571
Sales				
Ashok Agarwal	India		ashok.agarwal@elaracapital.com	+91 22 6164 8558
Hitesh Danak	India		hitesh.danak@elaracapital.com	+91 22 6164 8543
Karan Rathod	India		karan.rathod@elaracapital.com	+91 22 6164 8570
Lekha Nahar	India		lekha.nahar@elaracapital.com	+91 22 6164 8512
Prashin Lalvani	India		prashin.lalvani@elaracapital.com	+91 22 6164 8544
Shraddha Shrikhande	India			+91 22 6164 8567
			shraddha.shrikhande@elaracapital.com	
Sudhanshu Rajpal	India		sudhanshu.rajpal@elaracapital.com	+91 22 6164 8508
Joshua Saldanha	Asia		joshua.saldanha@elaracapital.com	+91 22 6164 8541
Anita Nazareth	Corporate Acc	ess, Conference & Events	anita.nazareth@elaracapital.com	+91 22 6164 8520
Tina D'souza	Corporate Acc		tina.dsouza@elaracapital.com	+91 22 6164 8595
Quantitative, Alternatives, S				
Sunil Jain	Quantitative &	Alternates	sunil.jain@elaracapital.com	+91 22 6164 8531
Nandish Patel	Quantitative &	Alternates	nandish.patel@elaracapital.com	+91 22 6164 8564
Biren Mehta	Head - Sales Tr	adina	biren.mehta@elaracapital.com	+91 22 6164 8500
Kalpesh Parekh	India	cang	kalpesh.parekh@ElaraCapital.com	+91 22 6164 8555
	India		manoj.murarka@elaracapital.com	
Manoj Murarka				+91 22 6164 8551
Anil Pawar	India		anil.pawar@elaracapital.com	+91 22 6164 8552
Nilesh Chheda	India		nilesh.chheda@elaracapital.com	+91 22 6164 8554
Nupur Barve	India		nupur.barve@elaracapital.com	+91 22 6164 8532
Research				
Dr Bino Pathiparampil	Head of Research	Healthcare, Pharmaceuticals, Strategy	bino.pathiparampil@elaracapital.com	+91 22 6164 8689
Amit Purohit	Analyst	Building Materials, FMCG, Paints	amit.purohit@elaracapital.com	+91 22 6164 8594
Ankita Shah	Analyst	Infrastructure, Ports & Logistics, Industrials	ankita.shah@elaracapital.com	+91 22 6164 8516
Biju Samuel	Analyst	Quantitative & Alternate Strategy	biju.samuel@elaracapital.com	+91 22 6164 8505
Gagan Dixit	Analyst	Aviation, Chemicals, Oil & Gas	gagan.dixit@elaracapital.com	+91 22 6164 8504
Garima Kapoor	Economist		garima.kapoor@elaracapital.com	+91 22 6164 8527
Harshit Kapadia	Analyst	Capital Goods, Consumer Electronics	harshit.kapadia@elaracapital.com	+91 22 6164 8542
Jay Kale, CFA	Analyst	Auto & Auto Ancillaries	jay.kale@elaracapital.com	+91 22 6164 8507
Karan Taurani		Media & Entertainment, Alcobev, QSR, Internet		+91 22 6164 8513
	Analyst			
Prakhar Agarwal	Analyst	Banking & Financials	prakhar.agarwal@elaracapital.com	+91 22 6164 8502
Prashant Biyani	Analyst	Agrochemicals, Fertilisers, Hotels, Sugar	prashant.biyani@elaracapital.com	+91 22 6164 8581
Prerna Jhunjhunwala	Analyst	Textiles, Retail	prerna.jhunjhunwala@elaracapital.coi	m +91 22 6164 8519
Rahul Jain, CFA	Analyst	Real Estate	rahul.jain@elaracapital.com	+91 22 6164 8500
Ravi Sodah	Analyst	Cement, Metals & Mining	ravi.sodah@elaracapital.com	+91 22 6164 8517
Rupesh Sankhe	Analyst	Utilities, Renewables	rupesh.sankhe@elaracapital.com	+91 22 6164 8518
Shweta Daptardar	Analyst	Diversified Financials, Non-Lending Financials	shweta.daptardar@elaracapital.com	+91 22 6164 8559
Saurabh Mitra	Sr. Associate	Cement, Metals & Mining	saurabh.mitra@elaracapital.com	+91 22 6164 8546
Aditya Jaiswal	Associate	Strategy	aditya.jaiswal@elaracapital.com	+91 22 4204 8683
Amogh Deshpande	Associate	Aviation, Chemicals, Oil & Gas	amogh.deshpande@elaracapital.com	+91 22 4204 8664
Bhavi Shah	Associate	Cement, Metals & Mining	bhavi.shah@elaracapital.com	+91 22 6164 8521
Devarshi Raj	Associate	Diversified Financials, Non-Lending Financials	devarshi.raj@elaracapital.com	+91 22 6164 8500
Gnyan Thaker	Associate	Textiles, Retail	gnyan.thaker@elaracapital.com	+91 22 6164 8500
Jinesh Kothari	Associate	Infrastructure, Ports & Logistics	jinesh.kothari@elaracapital.com	+91 22 6164 8500
Kartik Bhandari		Aviation, Chemicals, Oil & Gas	kartik.bhandari@elaracapital.com	+91 22 6164 8500
	Associate			
Kartik Solanki	Associate	Banking & Financials	kartik.solanki@elaracapital.com	+91 22 4204 8604
Kashish Thakur	Associate	Healthcare, Pharmaceuticals	kashish.thakur@elaracapital.com	+91 22 6164 8569
Keval Shah	Associate	Strategy	keval.shah@elaracapital.com	+91 22 4204 8669
Mihir Vora	Associate	Auto & Auto Ancillaries	mihir.vora@elaracapital.com	+91 22 6164 8500
Mudit Kabra	Associate	Capital Goods, Consumer Electronics	mudit.kabra@elaracapital.com	+91 22 4204 8611
Nemish Sundar	Associate	Capital Goods, Consumer Electronics	nemish.sundar@elaracapital.com	+91 22 4204 8683
Nishant Chowhan, CFA	Associate	Auto & Auto Ancillaries	nishant.chowhan@elaracapital.com	+91 22 4204 8667
Palak Shah	Associate	Banking & Financials	palak.shah@elaracapital.com	+91 22 4204 8682
Ragini Pande	Associate	Utilities, Renewables	ragini.pande@elaracapital.com	+91 22 6164 8500
Rohit Harlikar	Associate	Building Materials, FMCG, Paints	rohit.harlikar@elaracapital.com	+91 22 6164 8562
Rounak Ray	Associate	Media & Entertainment, Alcobev, QSR, Internet	t rounak.ray@elaracapital.com	+91 22 4204 8684
Runit Kapoor	Associate	Healthcare, Pharmaceuticals	runit.kapoor@elaracapital.com	+91 22 6164 8500
Shweta Roy	Associate	Economics	shweta.roy@elaracapital.com	+91 22 6164 8500
Subhankar Sanyal	Associate	Economics	subhankar.sanyal@elaracapital.com	+91 22 4204 8688
Tanvi Tambat	Associate	Real Estate	tanvi.tambat@elaracapital.com	
				+91 22 6164 8537
Ujwal Wadighare	Associate	Agrochemicals, Fertilisers, Hotels, Sugar	ujwal.wadighare@elaracapital.com	+91 22 4204 8684
Vidhi Puj	Associate	Building Materials, FMCG, Paints	vidhi.puj@elaracapital.com	+91 22 4204 8692
Vinayak Patil	Database		vinayak.patil@elaracapital.com	+91 22 6164 8510
Priyanka Sheth	Editor		priyanka.sheth@elaracapital.com	+91 22 6164 8568
Prakriti Singh	Editor		prakriti.singh@elaracapital.com	+91 22 6164 8500
Gurunath Parab	Production		gurunath.parab@elaracapital.com	+91 22 6164 8515
			jinesh.bhansali@elaracapital.com	
Jinesh Bhansali	Production		Jii iesi i.bi iai isall@elatacapitai.com	+91 22 6164 8537

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg,
Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500

CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933

Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018 Investor Grievance Email ID: <u>investor.grievances@elaracapital.com</u> - Tel. +91 22 6164 8509 Compliance Officer: Mr. Anand Rao - Email ID: <u>anand.rao@elaracapial.com</u> - Tel. +91 22 6164 8509